Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Recommendation of “Moderate Buy” from Brokerages

by · The Markets Daily

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $8.3333.

Several research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen lowered Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Friday, December 12th.

View Our Latest Report on Autolus Therapeutics

Institutional Investors Weigh In On Autolus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its stake in shares of Autolus Therapeutics by 6.9% in the 1st quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company’s stock worth $41,992,000 after buying an additional 1,746,020 shares during the last quarter. Mak Capital One LLC lifted its holdings in Autolus Therapeutics by 53.5% in the third quarter. Mak Capital One LLC now owns 26,017,616 shares of the company’s stock valued at $42,409,000 after acquiring an additional 9,062,518 shares during the period. Armistice Capital LLC lifted its holdings in Autolus Therapeutics by 30.0% in the third quarter. Armistice Capital LLC now owns 15,600,000 shares of the company’s stock valued at $25,428,000 after acquiring an additional 3,600,000 shares during the period. TFG Asset Management GP Ltd boosted its position in Autolus Therapeutics by 10.5% in the second quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock worth $21,660,000 after purchasing an additional 900,000 shares during the last quarter. Finally, Schroder Investment Management Group grew its stake in shares of Autolus Therapeutics by 133.7% during the 3rd quarter. Schroder Investment Management Group now owns 8,433,253 shares of the company’s stock valued at $13,409,000 after purchasing an additional 4,824,763 shares during the period. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Stock Performance

NASDAQ:AUTL opened at $1.70 on Friday. The firm has a 50-day simple moving average of $1.48 and a two-hundred day simple moving average of $1.79. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $2.80. The firm has a market cap of $452.44 million, a P/E ratio of -2.05 and a beta of 2.01.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). The firm had revenue of $21.19 million during the quarter, compared to analysts’ expectations of $21.08 million. Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%. On average, equities research analysts predict that Autolus Therapeutics will post -0.94 EPS for the current year.

Autolus Therapeutics Company Profile

(Get Free Report)

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

Featured Stories